[{"orgOrder":0,"company":"InfoRLife SA","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Clindamycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InfoRLife SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InfoRLife SA \/ Navamedic","highestDevelopmentStatusID":"12","companyTruncated":"InfoRLife SA \/ Navamedic"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Clindamycin Hcl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.

                          Brand Name : IDP-126

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 01, 2023

                          Lead Product(s) : Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : Clindamycin hydrochloride is a bacteriostatic which inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome.

                          Brand Name : Cleocin-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 14, 2023

                          Lead Product(s) : Clindamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          InfoRLife SA

                          Country arrow
                          SupplySide West 2024
                          Not Confirmed

                          InfoRLife SA

                          Country arrow
                          SupplySide West 2024
                          Not Confirmed

                          Details : Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract.

                          Brand Name : Clindamycin-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Clindamycin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Navamedic

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank